HC Wainwright Has Bullish Estimate for ARQT Q2 Earnings

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) - Research analysts at HC Wainwright lifted their Q2 2025 EPS estimates for Arcutis Biotherapeutics in a research report issued to clients and investors on Wednesday, May 7th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.20) for the quarter, up from their previous estimate of ($0.22). HC Wainwright has a "Buy" rating and a $19.00 price objective on the stock. The consensus estimate for Arcutis Biotherapeutics' current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics' Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.73) EPS and FY2026 earnings at ($0.01) EPS.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01. Arcutis Biotherapeutics had a negative return on equity of 119.11% and a negative net margin of 140.97%. The firm had revenue of $65.85 million during the quarter, compared to analysts' expectations of $64.80 million.

A number of other research analysts have also weighed in on the stock. Mizuho lifted their price target on shares of Arcutis Biotherapeutics from $20.00 to $21.00 and gave the company an "outperform" rating in a research note on Wednesday, February 26th. The Goldman Sachs Group lifted their price target on Arcutis Biotherapeutics from $13.00 to $15.00 and gave the company a "neutral" rating in a research note on Thursday, February 27th. Guggenheim reissued a "buy" rating on shares of Arcutis Biotherapeutics in a research report on Thursday, April 3rd. Jefferies Financial Group boosted their target price on Arcutis Biotherapeutics from $16.00 to $19.00 and gave the company a "buy" rating in a research note on Tuesday, March 11th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $20.00 price target on shares of Arcutis Biotherapeutics in a research note on Wednesday, April 9th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $18.80.

Arcutis Biotherapeutics Stock Down 4.0%

Shares of NASDAQ ARQT traded down $0.57 during mid-day trading on Friday, reaching $13.82. 2,047,666 shares of the company's stock were exchanged, compared to its average volume of 2,381,029. Arcutis Biotherapeutics has a twelve month low of $6.99 and a twelve month high of $17.75. The company has a current ratio of 2.46, a quick ratio of 2.38 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of -7.72 and a beta of 1.87. The business has a fifty day simple moving average of $14.77 and a 200 day simple moving average of $13.31.

Hedge Funds Weigh In On Arcutis Biotherapeutics

A number of institutional investors have recently bought and sold shares of ARQT. GF Fund Management CO. LTD. acquired a new position in shares of Arcutis Biotherapeutics during the 4th quarter worth approximately $34,000. Venturi Wealth Management LLC bought a new position in shares of Arcutis Biotherapeutics during the fourth quarter worth approximately $46,000. Amalgamated Bank lifted its holdings in shares of Arcutis Biotherapeutics by 39.4% during the first quarter. Amalgamated Bank now owns 3,723 shares of the company's stock worth $58,000 after buying an additional 1,053 shares in the last quarter. KBC Group NV acquired a new stake in shares of Arcutis Biotherapeutics in the first quarter valued at approximately $84,000. Finally, Nkcfo LLC acquired a new position in Arcutis Biotherapeutics in the 1st quarter valued at $109,000.

Insider Buying and Selling at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, insider Todd Franklin Watanabe sold 1,500 shares of the company's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $17.52, for a total transaction of $26,280.00. Following the sale, the insider now directly owns 927,414 shares of the company's stock, valued at approximately $16,248,293.28. This represents a 0.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Patrick Burnett sold 3,871 shares of Arcutis Biotherapeutics stock in a transaction dated Thursday, May 8th. The shares were sold at an average price of $13.59, for a total transaction of $52,606.89. Following the completion of the transaction, the insider now directly owns 115,468 shares of the company's stock, valued at approximately $1,569,210.12. This trade represents a 3.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 36,662 shares of company stock worth $527,326 over the last ninety days. 9.50% of the stock is currently owned by corporate insiders.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.